Eisbach Bio Announces First Patient Dosed in Phase 1/2 Trial for EIS-12656, a First-In-Class Allosteric Inhibitor of ALC1 in Refractory Advanced Solid Tumors

Eisbach | 9/16/24

Can Investors Both Earn Returns and End Cancer?

Chief Investment Officer | 7/19/24

Eisbach and Cancer Focus Fund Announce $4.5 Million Investment to Support First-in-Human Phase 1/2 Trial of EIS-12656 for Refractory Advanced Solid Tumors

GolbalNewswire | 3/21/24

Nectin Therapeutics Adds Combination Therapy Arm and Expands Sites in Phase 1 Clinical Trial of Its First-in-Class Anti-PVR Immune-Oncology Agent

PR Newswire | 12/18/2023

March Biosciences and Cancer Focus Fund Announce $4.8 Million Investment to Support a Phase 2 Clinical Trial of Novel CAR-T Therapy for T-Cell Lymphoma

March Biosciences | 11/9/23

Cancer Focus Fund invests $4.8M into Houston-based March Biosciences

March Biosciences | 11/9/23

ImmunoGenesis Doses First Patient in Phase 1a/1b Clinical Trial of IMGS‑001 in Relapsed or Refractory Advanced Solid Tumors

ImmunoGenesis | 9/28/23

Houston Oncology Summit: MD Anderson’s VP of industry relations talks about partnering (Video)

BiotechTV | 09/21/23

Houston Oncology Summit: How the Cancer Focus Fund Can Help Small Biotechs Get Into Phase 1 Studies (Video)

BiotechTV | 09/21/23

ImmunoGenesis and Cancer Focus Fund Announce $4.5 Million Investment to Support First-in-Human Trial of IMGS-001 for Relapsed or Refractory Advanced Solid Tumors

ImmunoGenesis | 8/31/23

Myeloma Investment Fund Invests in Nectin Therapeutics to Evaluate Nectin’s Anti-PVR Lead Drug Candidate as a Treatment for Multiple Myeloma

BioSpace | 05/16/2023

Ovarian Cancer Survivor: Immunotherapy Clinical Trial Saved

MD Anderson Cancer Center | 5/2/23

ISA Pharmaceuticals And Cancer Focus Fund Announce $5 Million Investment To Support First- In-Human Trial Of ISA’s Novel Immunotherapy ISA103 In Uveal Melanoma

PR Newswire | 01/04/23

Drug Could Bring Immunotherapy To Millions Of Cancer Patients

No Camels | 12/29/22

Israeli Biotech Company Begins Trial For Cancer Immuno-Oncology Solution

The Jerusalem Post | 11/30/22

MD Anderson VC Arm Joins $25M Funding Round For Cancer Drug Company

Becker’s Healthcare | 11/30/22

Nectin Therapeutics Announces Extended Series A Financing to Over $25M and Initiation of Patient Dosing in Phase 1 Clinical Trial of NTX1088, First-in-Class Anti-PVR Targeted Immunotherapy for Treatment of Patients with Advanced Solid Tumors

PR Newswire | 11/30/22

Nectin Therapeutics Announces $5.4 Million Investment from Cancer Focus Fund to Support Phase 1 Study of First-in-Class Anti-PVR Targeted Immunotherapy

PR Newswire | 03/07/22

KAHR and Cancer Focus Fund Announce First Patient Dosed in Phase 1b Clinical Trial of Anti-CD47 Product Candidate DSP107 in Blood Cancers

PR Newswire | 02/17/2022

KAHR Receives Investment from Cancer Focus Fund to Support Phase 1/2 Study of KAHR’s Lead Anti-CD47 Candidate in Blood Cancers

PR Newswire | 05/26/2021

Mereo and Focus Fund Announce Etigilimab partnership with MD Anderson

Mereo BioPharma | 04/30/21

MD Anderson Brings Underdogs into the Fight Against Cancer with Focus Fund

BioSpace | 10/21/20

Focus Fund and MD Anderson Launch Investment Fund to Support Promising Investigational Cancer Therapies in Early-Stage Clinical Trials

PR Newswire | 10/20/20